We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck KGaA (MKGAF) Q2 Earnings Fall But View Raised
Read MoreHide Full Article
Merck KGaA (MKGAF - Free Report) is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.
The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.
The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.
The acquisition of Sigma-Aldrich led the company to gain access to an attractive set of established brands along with an efficient supply chain to support the delivery of over 300,000 products, thereby enabling it to serve life science customers all over the world.
The company’s lead candidate, avelumab, is being evaluated in phase III studies for several cancer indications, in collaboration with Pfizer.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The company’s second-quarter 2016 earnings per American Depositary Receipt (ADR) came in at 80 cents, compared to the year-ago figure of 90 cents.
Revenue: The company posted revenues of $4.3 billion in the reported quarter.
Key Stats: All three business units continued to perform well. Organic sales growth increased 5.1%, driven by Life Science and Healthcare segments. The acquisition of Sigma-Aldrich boosted sales in the reported quarter.
Guidance: For 2016, the company expects net sales in the range of €14.9–€15.1 billion. Backed by Sigma-Aldrich acquisition, the company expects a positive portfolio effect on sales in the low double-digit percentage range. Unfavorable foreign exchange is projected to impact sales by 3–5%.
Check back later for our full write up on earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck KGaA (MKGAF) Q2 Earnings Fall But View Raised
Merck KGaA (MKGAF - Free Report) is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.
The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.
The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.
The acquisition of Sigma-Aldrich led the company to gain access to an attractive set of established brands along with an efficient supply chain to support the delivery of over 300,000 products, thereby enabling it to serve life science customers all over the world.
The company’s lead candidate, avelumab, is being evaluated in phase III studies for several cancer indications, in collaboration with Pfizer.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The company’s second-quarter 2016 earnings per American Depositary Receipt (ADR) came in at 80 cents, compared to the year-ago figure of 90 cents.
Revenue: The company posted revenues of $4.3 billion in the reported quarter.
Key Stats: All three business units continued to perform well. Organic sales growth increased 5.1%, driven by Life Science and Healthcare segments. The acquisition of Sigma-Aldrich boosted sales in the reported quarter.
Guidance: For 2016, the company expects net sales in the range of €14.9–€15.1 billion. Backed by Sigma-Aldrich acquisition, the company expects a positive portfolio effect on sales in the low double-digit percentage range. Unfavorable foreign exchange is projected to impact sales by 3–5%.
MERCK KGAA Price
MERCK KGAA Price | MERCK KGAA Quote
Check back later for our full write up on earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>